Sanofi India Q3 Results: Net Profit Falls 32% to ₹617M, EBITDA Down 25%
Sanofi India's Q3 results showed across-the-board declines with net profit falling 32% to ₹617 million and revenue dropping 18% to ₹4.2 billion year-on-year. EBITDA performance also weakened, declining 25% to ₹903 million with margins compressing to 21.51% from 22.98%. Despite the challenging financial performance, the pharmaceutical company announced a final dividend of ₹48 per share for shareholders.
*this image is generated using AI for illustrative purposes only.
Sanofi India Limited has reported a notable decline in its third-quarter financial performance, with both revenue and profitability showing significant year-on-year contractions. The pharmaceutical company's latest quarterly results highlight the challenging operating environment faced during the period, though the company has announced a substantial dividend for shareholders.
Financial Performance Overview
The company's financial metrics for the third quarter demonstrate substantial declines across key parameters compared to the same period in the previous year.
| Metric | Q3 Current Year | Q3 Previous Year | Change |
|---|---|---|---|
| Net Profit | ₹617 million | ₹913 million | -32.42% |
| Revenue | ₹4.2 billion | ₹5.15 billion | -18.45% |
| EBITDA | ₹903 million | ₹1.2 billion | -24.75% |
| EBITDA Margin | 21.51% | 22.98% | -147 bps |
Revenue and Profitability Analysis
Sanofi India's revenue for the third quarter stood at ₹4.2 billion, representing a decline from ₹5.15 billion recorded in the corresponding quarter of the previous year. This revenue contraction of approximately 18.45% indicates reduced business activity during the quarter. The company's net profit performance showed a more pronounced decline, falling to ₹617 million compared to ₹913 million in the same period last year, representing a decrease of over 32% year-on-year.
EBITDA Performance
The company's EBITDA declined to ₹903 million from ₹1.2 billion in the previous year, marking a decrease of approximately 25%. The EBITDA margin compressed to 21.51% from 22.98% year-on-year, indicating pressure on operational efficiency and profitability during the quarter.
Dividend Announcement
Despite the challenging financial performance, Sanofi India has proposed a final dividend of ₹48 per share for shareholders, demonstrating the company's commitment to returning value to its investors.
Market Context
The financial results reflect the operational challenges faced by Sanofi India during the third quarter. All key financial metrics including revenue, net profit, and EBITDA have shown substantial year-on-year declines, suggesting the company encountered headwinds in its business operations during this period.
19
